These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 12025914

  • 21. Drug interactions with fibric acids.
    Lozada A, Dujovne CA.
    Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
    [Abstract] [Full Text] [Related]

  • 22. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
    Palel G, Coman A, Petrovanu R, Ungureanu D, Cojocaru M.
    Rev Med Chir Soc Med Nat Iasi; 1997 Aug; 101(3-4):120-2. PubMed ID: 10756782
    [Abstract] [Full Text] [Related]

  • 23. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 24. Fibrates: where are we now?
    Seth Loomba R, Arora R.
    Ther Adv Cardiovasc Dis; 2009 Feb 15; 3(1):91-6. PubMed ID: 19144670
    [Abstract] [Full Text] [Related]

  • 25. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G.
    Atherosclerosis; 1994 Dec 15; 111(2):161-74. PubMed ID: 7718018
    [Abstract] [Full Text] [Related]

  • 26. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO, Hjelm CJ, Canepo-Anson R.
    Ann Clin Biochem; 1996 Mar 15; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract] [Full Text] [Related]

  • 27. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J, Scheen AJ, Legat P, De Backer G, Van Gaal L, Velkeniers B, Kartounian J, Maes M, Hermans M.
    Rev Med Liege; 2009 Oct 15; 64(10):512-8. PubMed ID: 19911665
    [Abstract] [Full Text] [Related]

  • 28. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
    Liberopoulos E, Miltiadous G, Elisaf M.
    Diabetes Obes Metab; 2001 Apr 15; 3(2):97-8. PubMed ID: 11298731
    [Abstract] [Full Text] [Related]

  • 29. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC, Fievre JL, Dejean C, Martin A, Vandel B.
    Gastroenterol Clin Biol; 1992 Apr 15; 16(6-7):609. PubMed ID: 1526424
    [No Abstract] [Full Text] [Related]

  • 30. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Apr 15; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 31. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar 15; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 32. [Clinical trials of statins and fibrates --a meta-analysis].
    Stanulović V, Derić M, Popović J.
    Med Pregl; 2006 Mar 15; 59(5-6):213-8. PubMed ID: 17039901
    [Abstract] [Full Text] [Related]

  • 33. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
    Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G.
    Ann Clin Biochem; 1999 Jul 15; 36 ( Pt 4)():523-5. PubMed ID: 10456219
    [No Abstract] [Full Text] [Related]

  • 34. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.
    Pol Merkur Lekarski; 2003 Jul 15; 15(85):42-6. PubMed ID: 14593958
    [Abstract] [Full Text] [Related]

  • 35. Ciprofibrate--a profile.
    Betteridge DJ.
    Postgrad Med J; 1993 Jul 15; 69 Suppl 1():S42-7; discussion S47-9. PubMed ID: 8497456
    [Abstract] [Full Text] [Related]

  • 36. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
    Nagyová A, Raslová K, Ginter E.
    Physiol Res; 1998 Jul 15; 47(3):185-90. PubMed ID: 9803483
    [Abstract] [Full Text] [Related]

  • 37. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A, Karge E, Deufel T, Oelschlägers H, Fleck C.
    Arzneimittelforschung; 2008 Jul 15; 58(5):225-41. PubMed ID: 18589557
    [Abstract] [Full Text] [Related]

  • 38. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec 15; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 39. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C.
    Acta Clin Belg; 1991 Dec 15; 46(2):117-9. PubMed ID: 1649529
    [No Abstract] [Full Text] [Related]

  • 40. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999 Dec 15; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.